US EditionStudy: An Experimental Pill Reduces the Risk of Progression of Blood Cancer by More than 50%
Summary by Stirile Pro TV
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
The administration of AstraZeneca experimental pills, at the first sign of resistance to standard cancer treatments, reduced the risk of progress or decline by 56%, shows the data presented at the ASCO conference.
·Bucharest, Romania
Read Full Article
The administration of the ChamistraZeneca experimental pills in patients with cancer, in the first sign of resistance to standard therapy, reduced the risk of disease or death by half according to the results presented on Sunday at the meeting of the American Medical Oncology Society (ASCO) in Chicago. Experts say that these results could change medical practice, reports Reuters.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
